# Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients

Study · id `cardio:ct-nct01167153` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01167153](<https://clinicaltrials.gov/study/NCT01167153>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01167153

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 564 participants.

## Technical summary

Registry record NCT01167153. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-04 (actual). Results posted on 2012-06-01.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 564 participants (enrolled count; ClinicalTrials.gov record NCT01167153, source copy `cardio:ctgov-nct01167153-2012-06-01`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01167153, source copy `cardio:ctgov-nct01167153-2012-06-01`, retrieved 2026-10-26)
- Primary completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01167153, source copy `cardio:ctgov-nct01167153-2012-06-01`, retrieved 2026-10-26)
- Completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01167153, source copy `cardio:ctgov-nct01167153-2012-06-01`, retrieved 2026-10-26)
- Results first posted: 2012-06-01 (ClinicalTrials.gov record NCT01167153, source copy `cardio:ctgov-nct01167153-2012-06-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01167153, source copy `cardio:ctgov-nct01167153-2012-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01167153-2012-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
- Acronym: EXAM
- Condition: Hypertension
- Intervention (Drug): Valsartan/Amlodipine
- Intervention (Drug): Nifedipine
- Lead sponsor: Novartis
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Nifedipine (`cardio:nifedipine`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy (`cardio:pubmed-23963546`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of the valsartan/amlodipine combination and nifedipine gastrointestinal therapeutic system monotherapy on brachial pulse pressure and radial augmentation index in hypertensive patients (`cardio:pubmed-33734121`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d6fbdc8252cdb0bb79a49817fcab1a645cec9b0d8c45b45b36b6e4272f87f88f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
